- Drug Pipelines
- July 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Drug Pipelines
- November 2024
- 80 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Clinical Trials
- April 2024
- 240 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- February 2024
- 30 Pages
Global
From €3102EUR$3,250USD£2,599GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- September 2022
- 30 Pages
Global
From €3102EUR$3,250USD£2,599GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Clinical Trials
- January 2024
- 100 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- August 2023
- 295 Pages
Global
From €9067EUR$9,500USD£7,597GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €3102EUR$3,250USD£2,599GBP
- Report
- October 2024
- 104 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- December 2022
- 114 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- December 2022
- 83 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- May 2022
- 227 Pages
Global
From €3340EUR$3,500USD£2,799GBP
- Report
- May 2022
- 39 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- May 2022
- 59 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- May 2022
- 72 Pages
Global
From €2386EUR$2,500USD£1,999GBP

The Toll Like Receptor (TLR) market is a key component of drug discovery. TLRs are a family of proteins that recognize and respond to foreign molecules, such as bacteria and viruses. They play an important role in the body's immune system, helping to identify and respond to potential threats. TLRs are also involved in the development of autoimmune diseases, cancer, and other diseases. As such, they are a major target for drug discovery.
TLR-based drug discovery is a rapidly growing field, with many companies investing in research and development. Companies are developing TLR-based therapies for a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. These therapies are designed to target specific TLRs, allowing for more targeted and effective treatments.
Companies in the TLR market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more